Celltrion Eyes Remsima SC Launches In Canada And Australia

Company On Track To Launch At Least One Biosimilar Every Year By 2030

 
• By Akriti Seth
  
Start Launch
Celltrion is focused on launching subcutaneous infliximab in Canada and Australia, and adalimumab in Europe • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Products

More from Generics Bulletin